Form 4: Verona Pharma Executive Kathleen A. Rickard Sells Ordinary Shares

Kathleen A. Rickard, Chief Medical Officer of Verona Pharma plc, sold ordinary shares represented by American Depositary Shares (ADSs) on May 6, 2025, under a pre-arranged Rule 10b5-1 plan.

Summary

• Kathleen A. Rickard, the Chief Medical Officer of Verona Pharma plc, reported a transaction involving the sale of ordinary shares represented by American Depositary Shares (ADSs).
• The transaction occurred on May 6, 2025.
• A total of 114,984 ordinary shares were sold at a price of $8.8216 per share.
• The sale was executed under a Rule 10b5-1 plan adopted on December 11, 2024.
• Following the transaction, Rickard beneficially owns 2,546,472 ordinary shares.
• The price per share ranged from $8.675 to $9.015 during the multiple transactions.

Sentiment

Score: 5

Explanation: The document reports a routine transaction (sale of shares under a pre-arranged plan) by an executive, which is neither particularly positive nor negative.

Industry Context

Sales by company insiders are a common occurrence and are often planned in advance to avoid any perception of trading on non-public information. Rule 10b5-1 plans allow insiders to sell shares at predetermined times and prices.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Verona Pharma, Kathleen A. Rickard, Ordinary Shares, American Depositary Shares, ADS, Rule 10b5-1 plan, SEC Form 4, Sale of Shares, Insider Trading